menu

Medical Program: Breaking Down the KEYNOTE-189 Protocol for NSCLC

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Breaking Down the KEYNOTE-189 Protocol for NSCLC

close
Breaking Down the KEYNOTE-189 Protocol for NSCLC
Restart
Resume
Choose a format
Media formats available:
Details
Presenters
Comments
  • Sponsored by

  • Overview

    Tune in as Dr. Michael Shafique from the Moffitt Cancer Center explains the KEYNOTE-189 clinical trial, which investigated whether the addition of pembrolizumab to standard of care platinum-based chemotherapy would provide some survival benefit to patients with non-small cell lung cancer.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Sponsored by

  • Overview

    Tune in as Dr. Michael Shafique from the Moffitt Cancer Center explains the KEYNOTE-189 clinical trial, which investigated whether the addition of pembrolizumab to standard of care platinum-based chemotherapy would provide some survival benefit to patients with non-small cell lung cancer.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 7/2/20